Biogen’s growth strategy includes M&A deals and the drugmaker is making a big one with the $7.3 billion buyout of Reata Pharmaceuticals, a rare disease company whose main asset is the only ...
A Plano biotech firm is turning regulatory approval of its first commercial drug into an even bigger deal. Massachusetts-based Biogen Inc. announced Friday that it's buying Reata Pharmaceuticals in a ...
In the aftermath of the Food and Drug Administration’s Aduhelm debacle, the agency’s neuroscience chief Billy Dunn has another controversial approval decision to make. It will once again test his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results